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ABSTRACT 25 
Fluoroquinolones are among the drugs most extensively used for the treatment of 26 
bacterial infections both in human and veterinary medicine. Resistance to quinolones 27 
can be both chromosomal- and plasmid-mediated. The former mechanism is associated 28 
with mutations in the DNA gyrase and topoisomerase IV encoding genes as well as 29 
mutations in regulatory genes affecting different efflux systems, among others. We 30 
studied the role of the acquisition of a mutation in the gyrA gene in the virulence and 31 
protein expression of uropathogenic E. coli. The HC14366M strain carrying a mutation 32 
in the gyrA gene (S83L) was found to lose the capacity to cause both cystitis and 33 
pyelonephritis mainly due to a decrease in the expression of the fimA, papA, papB and 34 
ompA genes. The levels of expression of the fimA, papB and ompA genes were 35 
recovered on complementing the strain with a plasmid containing the gyrA wild-type 36 
gene. However, only a slight recovery was observed in the colonization of the bladder in 37 
the GyrA complement strain compared to the mutant strain in a murine model of 38 
ascending urinary tract infection. In conclusion, a mutation in the gyrA gene of 39 
uropathogenic E. coli reduced the virulence of the bacteria likely in association with the 40 
effect of DNA supercoiling on the expression of several virulence factors and proteins, 41 
thereby decreasing their capacity to cause cystitis and pyelonephritis.  42 
43 
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INTRODUCTION  44 
Fluoroquinolones are among the drugs most extensively used for the treatment of 45 
bacterial infections both in human and veterinary medicine. They act by inhibiting the 46 
DNA gyrase and topoisomerase IV which tetrameric enzymes constituted by two A 47 
subunits and two B subunits. These subunits are encoded by the gyrA and gyrB genes, 48 
respectively, in the case of the DNA-gyrase and by the parC and parE genes, 49 
respectively, in the case of topoisomerase IV (1). The quinolones bind the DNA and the 50 
topoisomerase forming a quinolone-DNA-topoisomerase complex, avoiding the 51 
transcription or replication of DNA (1). The main mechanism of quinolone resistance is 52 
the accumulation of mutations in these two enzymes (2). Quinolone resistance can also 53 
be caused by the acquisition of qnr, a plasmid-mediated horizontally transferable gene 54 
(3). Two additional plasmid-mediated mechanisms of resistance to quinolones have also 55 
been identified, the AAC(6´)-Ib-cr protein, a variant aminoglycoside acetyltransferase 56 
capable of reducing ciprofloxacin activity (4), and the efflux pump QepA (5).  57 
 58 
The primary cellular target of fluoroquinolones in E. coli is a type II topoisomerase 59 
(DNA gyrase) enzyme which is unique in catalyzing negative supercoiling of covalently 60 
closed circular double-stranded DNA in an ATP-consuming reaction and is therefore 61 
essential for maintenance of DNA topology. Topoisomerase IV has been shown to be  a 62 
secondary quinolone target in E. coli and decatenates the chromosome before cell 63 
division (6). Changes in DNA supercoiling in response to environmental factors 64 
contribute to the control of bacterial virulence (7). 65 
Quinolone- and fluoroquinolone-resistant uropathogenic E. coli (UPEC) strains display 66 
reduced virulence in the invasion of immunocompromised patients. By contrast, 67 
susceptible E. coli strains are more virulent and affect immunocompetent hosts, 68 
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showing a larger number of virulence factors contained in pathogenicity islands (PAIs) 69 
(8, 9). It has been demonstrated that a resistant E. coli strain becomes less virulent 70 
following the acquisition of a gyrA mutation (10), and that the loss of virulence by 71 
acquisition of quinolone resistance may take place before the acquisition of mutations 72 
and/or quinolone resistance levels (11).
The biological cost of quinolone resistance differs among different bacteria and depends 74 
on the level of resistance and the number of resistance mutations (12). 75 
  73 
In comparison to commensal strains UPEC has several virulence factors that allow it to 76 
colonize host mucosal surfaces, injure and invade host tissues, overcome host defense 77 
mechanisms and incite a host inflammatory response. 78 
Among these virulence factors, type 1 fimbriae, P-fimbriae and outer membrane 79 
proteins have an important role in several steps of urinary tract infection (UTI). Thus, 80 
type 1 pili promote adherence of UPEC to superficial bladder epithelial cells initiating a 81 
cascade of events that directly influence the pathogenesis of UTIs (13). In addition, type 82 
1 fimbriae have been associated with invasion of the bladder epithelial cells and the 83 
ability of the bacteria to replicate intra-cellularly, forming “internal biofilms” (14). 84 
P
On the other hand, the OmpA protein is critical for promoting persistent infection 87 
within the epithelium and has been associated with cystitis and intracellular survival 88 
(16). 89 
 fimbria (a mannose-resistant adhesin of UPEC) has been shown to be associated with 85 
acute pyelonephritis (at least 90% of acute pyelonephritis) (15). 86 
 90 
The aim of this study was to determine the role of the acquisition of a mutation in the 91 
gyrA gene in the virulence and protein expression of UPEC. 92 
93 
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MATERIAL AND METHODS 94 
Bacterial strains and selection of resistant mutants. Three strains of E. coli were 95 
used in this study: i) the HC14366 wild-type UPEC clinical isolate with a MIC of 96 
ciprofloxacin (CIP) of 0.008 mg/L; ii) its CIP-resistant mutant (E. coli HC14366M) 97 
with a mutation in the gyrA gene (S83L) and a MIC of CIP of 2 mg/L; and iii) the E. 98 
coli HC14366M mutant transformed with a plasmid carrying the wild-type gyrA gene, 99 
generating a complementation of the gyrA gene (E. coli HC14366MC) with a MIC of 100 
CIP of 0.064 mg/L. Strain HC14366-wt was grown at 37ºC on MacConkey plates in the 101 
presence of ciprofloxacin in a multi-step selection process to obtain strain HC14366-2 102 
(HC14366M), a ciprofloxacin-resistant mutant. Ciprofloxacin (Fluka, Steinheim, 103 
Germany) was only present in agar plates during the selection procedures, starting at 104 
0.004 mg/L (half of the MIC for HC14366-wt) and increasing 2-fold each step, until 105 
reaching a maximum concentration of 2 mg/L. Single colonies were selected at each 106 
step and named according to the ciprofloxacin concentration of selection (e.g., strain 107 
HC14366-0.016 was selected at a CIP concentration of 0.016 µg/mL).  108 
 109 
Antimicrobial susceptibility. Susceptibility to several antimicrobial agents was 110 
determined in the presence and absence of 20 mg/L of the efflux pump inhibitor Phe-111 
Arg-ß-naßhthylamide using the agar dilution method according to the CSLI (17) 112 
guidelines as described elsewhere (18). 113 
 114 
Virulence profile. The virulence profile was analyzed by PCR using gene-specific 115 
primers for 17 virulence genes including hemolysin (hly), cytotoxic necrotizing factor 116 
(cnf), autotransporter (sat), P-fimbriae (pap genes), type 1C fimbriae (foc), 117 
yersiniabactin (fyu), heat-resistant hemagglutinin (hra), S-fimbriae (sfa), invasin (ibeA), 118 
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adhesin (iha), aerobactin (aer), siderophores (iucC, iutA, iroN), and antigen 43 (ag43) 119 
(19). 120 
 121 
Motility and type 1 fimbriae expression. The motility of each isolate was analyzed by 122 
growth in mannitol agar. Expression of type 1 fimbriae was determined by agglutination 123 
of Saccharomyces cerevisiae by the procedure described by (20).  124 
 125 
Doubling time analysis. The strains were grown in LB media at 37ºC with shaking. 126 
The OD600 nm
 129 
 of each culture was measured in a CECIL CE2302 spectrum. Aliquotes 127 
were taken every 30 minutes along six hours (21).  128 
Animal model. The virulence of the strains was tested in a murine model of an 130 
ascending UTI protocol approved by the Danish Ministry of Justice Animal Ethics 131 
Committee (approval no. 2004/561-835) and described by (22). In short, mouse 132 
bladders were emptied by gently pressing the abdomen, and 50 µl (5 × 106 CFU) of 133 
each bacterial suspension was slowly inoculated transurethrally into 4 to 6 outbreed 134 
female albino CFW-1 mice (26 to 30 g; Harlan Netherlands, Horst, Netherlands) with 135 
the use of plastic catheters. The mice were housed 4 to 6 to a cage and were given free 136 
access to food and 5% glucose-containing water. Seventy-two hours after inoculation, 137 
urine was collected from each mouse. The mice were then euthanized by cervical 138 
dislocation, and the bladder and kidneys were removed and stored in Eppendorf tubes. 139 
The urine samples were processed the same day by spotting (20 μl) of a series of 10-140 
fold dilutions (100 to 10−6) in duplicate on bromothymol blue agar plates (SSI 141 
Diagnostika, Hillerød, Denmark). The bladder and kidneys were stored in 0.9% saline 142 
solution and were then incubated at room temperature for 1 h and subsequently 143 
7 
 
homogenized using a TissueLyser (Qiagen, Ballerup, Denmark). Plates for bacterial 144 
counting were processed as described above. The detection limit was 25 CFU/sample. 145 
The experiment was repeated twice. The three strains were tested in parallel on the same 146 
day and using the same batch of mice.  147 
 148 
RT-PCR. The strains were grown to an OD620nm
CCGGTA-3´) generating an amplicon of about 550 bp; the fimA gene 156 
(GGACAGGTTCGTACCGCATC/ACGTTGGTATGACCCGCATC) generating an 157 
amplicon of about 250 bp; the marA gene (CATTCATAGCTTTTGGACTGGAT/GTG 158 
 of 0.5 in Luria-Bertani medium. One 149 
ml was centrifuged and RNA from the pellet was extracted with TriReagent solution 150 
(Ambion, Spain) following the manufacturer’s instructions, and treated with 1 µl of 151 
DNA-free DNase (Ambion, Spain). RT-PCR was performed using the AccessQuick 152 
RT-PCR System (Promega, Spain). Five hundred nanograms of RNA were taken as 153 
template. Specific primers were used for the housekeeping gap gene (used as an 154 
expression control) (5’-GTATCAACGGTTTTGGCCG-3´/5´-AGCTTTAGCAGCA 155 
TAAAAAGCGCGATTCGCC) generating an amplicon of about 150 bp; the papA gene 159 
(GGGGCAGGGTAAAGTAACTT/CAGGGTATTAGCATCACCT); and the papI gene 160 
(CGATGAGTGAATATATGAA/CACGAATTCTTATTAAGTTGTGGAAGA).The 161 
PCR reaction was performed under the following conditions: one cycle of 45 minutes at 162 
45°C and 3 minutes at 94°C, followed by 26-28 cycles (fimA, marA, papA and papI 163 
genes) or 16 cycles (gap gene) of 1 minute at 94°C, 1 minute at 56°C, and 1 minute at 164 
72°C. The PCR products were run in commercial acrylamide gels (GeneGel Excel, GE 165 
Healthcare, Spain) and stained with the Plus One DNA Silver staining kit (GE 166 
Healthcare, Spain). All experiments were carried out in triplicate.  167 
 168 
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Protein analysis. Purification of whole proteins was performed using a sonicator-based 169 
method (23). Two-dimensional gels electrophoresis was run for the protein extracts of 170 
these three strains and stained using a silver staining protocol to compare their patterns. 171 
The spots in the HC14366 wild-type E. coli showing a variation in the level of 172 
abundance compared to the mutant strain (E. coli HC14366M) and restored in the 173 
transformed E. coli (E. coli HC14366MC), were sliced and characterized by mass 174 
spectrometry analysis (MALDI TOF-TOF).   175 
 176 
Real-time experiments. RNA was extracted from exponential cultures and isolated 177 
using RNAprotect Bacteria Reagent (Qiagen, Hilden,Germany) and the RNeasy Mini 178 
Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. All 179 
samples were treated with the DNA-free DNase kit (Ambion, Austin, TX) to remove 180 
contamination by genomic DNA, and a PCR was performed to confirm the loss of 181 
DNA. In this step, quantification of the RNA was carried out by EPOCH (Biotek). 182 
Three independent RNA extractions of each sample were performed. Using the retro-183 
transcription kit (Takara Cat#RR037Q), 500 ng of each RNA sample were used to 184 
perform reverse transcription. The cDNA template was diluted 1/5 for the RT-PCR. The 185 
ompA, ompF (both encoding two outer membrane proteins related to virulence), and 186 
papB (one of the transcription regulators of papA) genes were selected and the 16S gene 187 
was used as an endogenous control. Primer Express® software was used to design the 188 
primers to amplify these genes. After several assays with different primer 189 
concentrations, a concentration of 3 µM was found to be optimal. Amplification was 190 
performed using a StepOne™ Real-Time PCR System (Applied Biosystems) using the 191 
Sybr Premix Ex Taq_”Tli RNaseH Plus” kit (Takara) and the Universal Thermal 192 
Cycling conditions: 2 min at 50ºC (UNG activation), 10 min at 95ºC (enzyme 193 
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activation) followed by 40 cycles of 95 ºC for 15 s (denaturation) and 60 ºC 194 
(anneal/extension) for 1 min. Data was analyzed with the StepOne software v2.0 and the 195 
relative level of expression of each sample (2-∆∆CT
 197 
) was obtained. 196 
Statistical analysis. Data from the animal model experiments was analyzed using the 198 
one factor ANOVA with the SPSS software version 20. P-values less than 0.05 were 199 
considered to be significant. 200 
201 
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RESULTS 202 
 203 
The HC14366 UPEC strain was submitted to a multi-step selection process in the 204 
presence of CIP, starting at 0.004 mg/L (half of the MIC for the wild-type strain) and 205 
increasing 2-fold each step until reaching a maximum concentration of 5.12 mg/L. The 206 
intermediate mutant HC14366-2.56 (HC14366M) was chosen because it has a mutation 207 
in the QRDR of the gyrA gene but not in the gyrB, parC or parE genes. This mutation is 208 
found in codon 83 from Ser to Leu.  209 
The HC14366M mutant was transformed with a plasmid carrying the wild-type gyrA 210 
gene. The resulting strain (HC14366MC) showed a MIC to CIP of 0.064 mg/L. The 211 
MICs of different antimicrobial agents in the presence/absence of the efflux pump 212 
inhibitor Phe-Arg-ß-naphthylamide were also determined (Table 1). The complemented 213 
strain HC14366MC was found to be less resistant to CIP, nalidixic acid, norfloxacin and 214 
chloramphenicol than the mutant strain HC14366M.  215 
The HC14366 wild-type strain and its mutants showed the following virulence factors: 216 
hemolysin (hly), cytotoxic necrotizing factor (cnf1), autotransporter (sat), yersiniobactin 217 
(fyuA), type 1 fimbriae (fimA), P-fimbriae (pap genes), hemagglutinin (hra gene), S-218 
fimbriae (sfaS), and siderophore (iroN). The HC14366M and HC14366MC strains 219 
showed a decrease in the motility through mannitol and in the expression of type 1 220 
fimbriae in comparison with the wild-type strain. Therefore, expression of type 1 221 
fimbriae and motility are not affected by a mutation in the gyrA gene. 222 
The doubling time of the three strains was studied, showing that a mutation in the gyrA 223 
gene affects bacterial growth, and the complemented strain showed a higher doubling 224 
time value than the mutant strain but could not fully recover the wild-type levels (data 225 
not shown).   226 
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These three strains were inoculated into six mice of an animal model of ascending UTI, 227 
and urine, bladder and kidney samples were collected. It is noteworthy that the 228 
HC14366M strain lost the capacity to cause cystitis and pyelonephritis, with an average 229 
of 105 CFU/ml, 102 CFU and 100 CFU found in urine, the bladder and the kidneys, 230 
respectively, compared with the values observed in the wild-type strain: 108 CFU/ml 231 
urine (p= 0.032), 107 CFU/bladder (p= 0.002) and 104 CFU/two kidneys (p= 0.042). 232 
The HC14366MC strain increased the capacity to cause cystitis showing around 104 
In order to determine the cause of the decrease of colonization in the mutant strain, RT-236 
PCR were carried out using specific primers for the fimA and papA genes involved in 237 
cystitis and pyelonephritis, respectively. The expression of both genes was found to be 238 
decreased in the HC14366M strain and only fimA expression was recovered in the 239 
complemented strain. On the other hand, marA was overexpressed in the mutant and 240 
complemented strains in comparison with the wild-type strain (Fig. 2).  241 
(p= 233 
0.011) CFU in the bladder but did not have the capacity to cause pyelonephritis (p= 234 
0.043) (Fig. 1).  235 
In order to study the cause of the decrease in the expression of the papA gene in both the 242 
mutant and complemented strain, we studied the regulators Lrp, PapI and PapB. A total 243 
inhibition of papB and papI gene expression was found in the HC14366M strain, being 244 
papB expression recovered in the HC14366MC strain (Fig. 4). 245 
Protein analysis revealed changes in protein expression in the three strains (Table 2, Fig. 246 
3). These changes included proteins implicated in cellular permeability, metabolic 247 
functions and DNA replication. Among the proteins with decreased expression in the 248 
HC14366M strain but with the recovery of wild-type levels in the HC14366MC strain 249 
we found the outer membrane protein A precursor, aspartate ammonia-lyase, the 250 
maltose-binding periplasmic protein, tryptophanyl-tRNA synthetase, the D-ribose 251 
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periplasmic binding protein, the pyruvate kinase I protein, and a phosphate 252 
acetyltransferase. On the other hand, the DNA-directed RNA polymerase, two 253 
dehydrogenases and the heat shock protein Hsp90 were overexpressed in the 254 
HC14366M but not in the HC14366wt or HC14366MC strains. In addition, the 255 
expression of the outer membrane protein F (porin) decreased in the HC14366M and its 256 
complemented strain (Table 2). 257 
RNA expression of the genes encoding some proteins possibly related to virulence 258 
(MalE, OmpA, OmpF, and PapB) was analyzed confirming the data obtained in the 259 
protein experiments (Fig. 4). 260 
 261 
 262 
 263 
 264 
 265 
 266 
267 
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DISCUSSION 268 
Since their introduction into clinical use in 1983, fluoroquinolones have played an 269 
essential role in the treatment of infectious diseases caused by enteric bacteria such as 270 
E. coli. However, a progressive increase in the emergence of fluoroquinolone-resistant 271 
strains has been observed in the last decades (24). Two types of mutants are 272 
predominantly found among clinical isolates: low-level resistant isolates (CIP MIC<2 273 
mg/L) frequently carrying a single gyrA mutation which generates a substitution of 274 
serine 83 to leucine (S83L) and high-level resistant isolates (MIC >4 mg/L) carrying 275 
two gyrA mutations in addition to mutations affecting serine 80 (S80) and glutamic acid 276 
84 (Glu84) in parC (21).   277 
The “in vitro” mutant obtained in our laboratory presented the single gyrA mutation 278 
most frequently found in clinical isolates (S83L). 279 
The level of global supercoiling in E. coli,  is mainly regulated by the DNA-gyrase (25). 280 
The accumulation of mutations in genes which encode for the essential enzymes 281 
involved in the control of DNA topology can affect the regulation of the degree of 282 
supercoiling. Thus, the expression of supercoiling-regulated genes in laboratory mutants 283 
is commonly associated with a fitness cost (probably due to the overexpression of an 284 
unknown efflux system), observed as a reduced growth rate and/or virulence in the 285 
absence of antibiotic (21). In accordance with the results obtained in our study, Bagel et 286 
al. (21) 
 292 
observed that a single S83L mutation in the gyrA gene showed an increase in the 287 
doubling time and, therefore, a decrease in the growth rate in comparison with the wild-288 
type strain. Moreover, in the present study, an increase was observed in the doubling 289 
time when plasmid encoded gyrA+ was introduced into mutant strain, albeit not to wild-290 
type levels. These results indicate that gyrA is involved in the rate of E. coli growth.  291 
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Changes in DNA supercoiling affect antimicrobial resistance levels. Thus, the 293 
introduction of a plasmid-encoded allele of gyrA+ in the HC14366M strain caused a 294 
reduction in the MICs of CIP and nalidixic acid (from 2.56 to 0.064 mg/L and from 295 
>256 to 6 mg/L, respectively), indicating that this mutation contributes to the expression 296 
of quinolone resistance as described previously (21). 297 
Changes in DNA supercoiling can also contribute to the control of bacterial virulence 298 
(7). The mutation in the gyrA gene in the strain under study seemed to cause changes in 299 
its capacity to develop cystitis and pyelonephritis. Firstly, a reduction in type 1 fimbriae 300 
expression was shown by the mutant strain, preventing it from colonizing the bladder 301 
and, therefore, from causing cystitis. The finding that the introduction of a plasmid-302 
encoded gyrA+ did not significantly (p = 0.456) modify the capacity of the mutant strain 303 
to cause cystitis could be due to the fact that transcription from the fimA promoter was 304 
not totally affected by changes in DNA supercoiling as demonstrated by Dove et al. (26) 305 
on introducing a topA:Tn10 mutation or inhibiting the DNA-gyrase with the antibiotic 306 
novobiocin.  307 
Another change in virulence as a consequence of the acquisition of a mutation in the 308 
gyrA gene is a decrease in P-fimbriae expression leading a decrease in the capacity of 309 
the mutant strain to cause pyelonephritis. Expression of pyelonephritis-associated pili 310 
(Pap) in E. coli is under a phase-variation control mechanism in which individual cells 311 
alternate between pili+ (ON) and pili- (OFF) states through a process involving DNA 312 
methylation by deoxyadenosine methylase (Dam) and regulation via Lrp (27).  313 
Control of P-fimbriae expression also requires the action of PapI, a positive regulator 314 
that increases the affinity of Lrp for the binding sites, and PapB, the second specific 315 
regulator of the Pap operon, that plays an important role at a transcriptional level 316 
primarily by coordinating the expression of papBA and papI promoters (28). 317 
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In our strain, Lrp and PapI seem to be functional. However, a decrease in papB and papI 318 
expression was found in the mutant strain, with only papB expression being recovered 319 
in the complemented strain, albeit not at wild-type levels, and not being reflected in the 320 
ability of the complemented strain to colonize the kidney.  321 
Tessier MC et al. (29) studied F165 adhesin from E. coli. This adhesin belongs to the 322 
family of Pap-related fimbriae the expression of which is mediated by regulatory 323 
proteins such as Lrp, Dam-methylase, and by FooI and FooB. They found that 324 
inactivation of the gyrA gene caused a decrease in supercoiling producing a decrease in 325 
fooB expression and inducing a decrease in P-fimbriae expression. FooB is the 326 
equivalent of PapB in the P-fimbriae. The decrease of papB expression found in the 327 
present study could explain the decrease of P-fimbriae expression, thereby making the 328 
mutant strain unable to adhere to renal epithelial cells and cause pyelonephritis. 329 
Although papB expression was recovered in the complemented strain, the finding that it 330 
did not recover the ability to cause pyelonephritis may be due to the fact that other P-331 
fimbriae regulator (as PapI) were not affected by the inclusion of the plasmid containing 332 
the functional gyrA gene.     333 
Finally, the introduction of a mutation in the gyrA gene may cause changes in the 334 
expression of different proteins.  335 
Treatment with fluoroquinolones can induce heat shock responses (30). For example, 336 
levofloxacin produced an overexpression of several heat shock proteins when the strain 337 
was incubated with this antibiotic (30), being HtpG one of these proteins. HtpG is the 338 
bacterial homologue of Hsp90 (presented in yeast and humans) and is dispensable under 339 
non-stress conditions. HtpG comprises a large fraction (0.36%) of all the proteins in E. 340 
coli growing at 37ºC (31). In the present study, this protein was found to be 341 
overexpressed in the mutant strain and its expression achieved wild-type levels in the 342 
16 
 
strain complemented with the plasmid-encoded gyrA+. Therefore, the transcription of 343 
HtpG is mainly regulated by supercoiling.  344 
OmpA is a major, monomeric, integral protein component of the outer bacterial 345 
membrane that functions as a critical determinant of intracellular virulence for UPEC, 346 
promoting persistent infection within the bladder epithelium (32). The fact that the 347 
HC14366M strain has a significantly lower bladder colonization rate than the HC14366 348 
wild-type strain may be in accordance with the decrease in the expression of this gene. 349 
The recovery of ompA expression together with that of fimA could explain the increase 350 
in bladder colonization from 102 CFU/g to 104
OmpF is also one of the major outer membrane proteins of E. coli, the expression of 352 
which is extremely and specifically sensitive to the level of DNA supercoiling (33). Our 353 
results are in accordance with the study by Graene-Cook et al. (33) in which the finding 354 
of a gyrA mutant strain led to a decrease in OmpF expression probably due to 355 
overexpression of marA (34).  356 
 CFU/g. 351 
 357 
 358 
In conclusion, a mutation in the gyrA gene of UPEC causes a decrease in the virulence 359 
of the bacteria due to the effect of DNA supercoiling on the expression of several 360 
virulence factors and proteins, thereby decreasing the capacity to cause cystitis and 361 
pyelonephritis. This study demonstrates the relationship between virulence and the 362 
acquisition of antimicrobial resistance“in vivo”. 363 
364 
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Figure 1. Results of an animal model of ascending urinary tract infection. 502 
 A) HC14366 wild-type strain; B) HC14366M strain; C) HC14366MC strain. 503 
Vertical axis, cfu/ml urine/gr. Bladder/ two kidneys 504 
 505 
Figure 2. RT-PCR of the strains studied. 506 
MC, HC14366MC strain; M, HC14366M strain; wt, HC14366 wild-type strain. 507 
 508 
Figure 3. 2D-SDS page protein gels.  509 
A) HC14366 wild-type strain; B) HC14366M strain; C) HC14366MC strain. 510 
 511 
Figure 4. Real-time PCR of the genes selected. 512 
HC14366, wild-type strain; HC14366M, mutant strain; HC14366MC, complemented 513 
strain. 514 
 515 
Table 1.  Minimal Inhibitory Concentration (mg/L) of the strains under study. 
Strain CIP NAL NAL+Inh NX  NX+Inh   C C+Inh 
HC14366wt 0.008 3 0.19 0.047 0.125 6 2 
HC14366M 2.56 >256 >256 6 16 24 4 
HC14366MC 0.064 6 0.38 0.5 0.5 16 3 
HC14366wt, wild-type strain; HC14366M, gyrA-mutant strain; HC14366MC, 
complemented strain; CIP: ciprofloxacin; NAL, nalidixic acid; Inh, efflux pump 
inhibitor Phe-Arg-ß-naßhthylamide; NX, norfloxacin; C, chloramphenicol. 
Table 2. Proteins characterized by 2D-SDS PAGE. 
ID 
number 
Protein Spot intensity 
  HC14366wt HC14366M HC14366MC 
0J Aspartate ammonia-lyase +++ + +++ 
3J Glycerol kinase + - - 
6J Outer membrane protein (OmpF) ++ + - 
7J Maltose-binding periplasmic protein 
precursor 
+++ + ++ 
8J Aminomethyltransferase ++ + + 
9J Outer membrane protein A (OmpA) ++ - ++ 
11J PTS enzyme IIAB, mannose specific ++ - + 
12J D-ribose periplasmic binding protein +++ + ++ 
13J DNA-direct RNA polymerase + ++ + 
14J Pyruvate kinase I ++ + ++ 
15J 6-phosphogluconate dehydrogenase + ++ + 
16J Succinyl-CoA sinthetase + ++ ++ 
18J Duhydrolipoamide dehydrogenase ++ +++ ++ 
20J Tryptophanyl-tRNA synthetase + - + 
21J Phosphate acetyltransferase + - + 
22J HtpG, heat shock protein - + - 
24J Adenylsuccinate synthetase ++ - + 
25J Phosphoglycerate kinase +++ + ++ 
26J Tratrinate semialdehyde reductase + - + 
28J Isocitrate dehydrogenase - + - 
29J Cell division inhibitor + - ++ 
 
ID number, identification number from Figure 3. 
HC14366wt, wild-type strain; HC14366M, gyrA-mutant strain; HC14366MC, 
complemented strain. 
+++, high expression; ++, moderate expression; +, low expression; -, no protein 
expression.  




